Autophagy

Overview

Autophagy (from the Greek "auto" meaning self and "phagein" meaning to eat) is a highly conserved cellular degradation process in which cytoplasmic components — damaged organelles, protein aggregates, and intracellular pathogens — are enclosed in double-membrane vesicles (autophagosomes) and delivered to lysosomes for degradation and recycling. The process was first observed by Christian de Duve in the 1960s (who also coined the term), and its molecular machinery was elucidated by Yoshinori Ohsumi, who received the 2016 Nobel Prize in Physiology or Medicine for this work.

Autophagy operates at a basal level in virtually all cells, performing essential housekeeping by removing damaged or dysfunctional cellular components. Under stress conditions — nutrient deprivation, energy depletion, infection, hypoxia — autophagy is dramatically upregulated to provide recycled building blocks and eliminate threats to cellular integrity.

In peptide research and the broader longevity community, autophagy has attracted intense interest because of its role as a cellular rejuvenation mechanism. The mTOR pathway is the primary negative regulator of autophagy, and interventions that inhibit mTOR (fasting, caloric restriction, rapamycin) activate autophagy and are among the most robust lifespan-extending strategies in laboratory organisms. Several peptides intersect with autophagy regulation, either promoting or modulating this process.

How It Works

Types of Autophagy

Three main types of autophagy exist in mammalian cells:

Macroautophagy (commonly referred to simply as "autophagy")

• The best-characterized form; involves formation of a new double-membrane vesicle (autophagosome) that engulfs cytoplasmic cargo
• The form most relevant to longevity research and peptide biology
• Discussed in detail below

Microautophagy

• Direct invagination of the lysosomal membrane to engulf small portions of cytoplasm
• Less well characterized; may contribute to selective degradation of specific proteins

Chaperone-mediated autophagy (CMA)

• Selective degradation of individual proteins bearing a KFERQ-like motif
• Chaperone Hsc70 recognizes the motif and delivers the protein directly to the lysosome via LAMP-2A receptor
• Important for selective protein quality control; declines with age

The Macroautophagy Machinery

Macroautophagy proceeds through distinct stages, each governed by specific autophagy-related (ATG) proteins:

1. Initiation — the ULK1 complex

• The ULK1 complex (ULK1, ATG13, FIP200, ATG101) is the autophagy initiation switch
• Under nutrient-rich conditions, active mTORC1 phosphorylates ULK1 and ATG13, keeping the complex inactive
• When mTORC1 is inhibited (fasting, rapamycin, energy depletion), ULK1 is dephosphorylated and activated
• AMPK (activated by low energy/high AMP:ATP ratio) directly phosphorylates and activates ULK1, providing a second activation signal
• Active ULK1 translocates to autophagy initiation sites (typically ER-mitochondria contact sites)

2. Nucleation — the VPS34 complex

• Active ULK1 phosphorylates and activates the class III PI3K complex (VPS34, Beclin-1, VPS15, ATG14L)
• VPS34 generates phosphatidylinositol 3-phosphate (PI3P) on the isolation membrane (phagophore)
• PI3P recruits downstream effectors (WIPI proteins, DFCP1) to the phagophore
• Beclin-1 is a key regulatory node: its interactions with Bcl-2 (anti-apoptotic) link autophagy to cell survival decisions. Under nutrient-rich conditions, Bcl-2 sequesters Beclin-1; starvation or JNK-mediated Bcl-2 phosphorylation releases Beclin-1 to activate autophagy.

3. Elongation — two ubiquitin-like conjugation systems The phagophore expands to engulf cargo through two ubiquitin-like conjugation systems:

• ATG12-ATG5-ATG16L1 complex — ATG12 is covalently conjugated to ATG5 (catalyzed by ATG7 and ATG10). The ATG12-ATG5 conjugate associates with ATG16L1 to form a complex that acts as an E3-like ligase for the second conjugation system.

• LC3 lipidation (LC3-II formation) — LC3 (ATG8 in yeast) is cleaved by ATG4 to expose a C-terminal glycine (LC3-I). The ATG12-ATG5-ATG16L1 complex then catalyzes the conjugation of LC3-I to phosphatidylethanolamine (PE) on the autophagosome membrane, generating LC3-II. LC3-II is the definitive marker of autophagosomes and is widely used experimentally to measure autophagy flux.

4. Cargo selection (selective autophagy) While autophagy can be non-selective (bulk cytoplasmic degradation during starvation), much autophagy is highly selective, targeting specific cargo:

• Mitophagy — Selective degradation of damaged mitochondria. PINK1 accumulates on depolarized mitochondria and recruits Parkin (E3 ubiquitin ligase), which ubiquitinates outer membrane proteins. Ubiquitinated mitochondria are recognized by autophagy receptors (p62/SQSTM1, OPTN, NDP52) that bridge the cargo to LC3 on the autophagosome. Mitophagy is directly linked to mitochondrial function maintenance.
• Aggrephagy — Degradation of protein aggregates (via p62/SQSTM1)
• Xenophagy — Degradation of intracellular pathogens (bacteria, viruses)
• Lipophagy — Degradation of lipid droplets
• ER-phagy — Selective ER degradation

5. Fusion and degradation

• The completed autophagosome fuses with lysosomes to form an autolysosome
• Lysosomal acid hydrolases degrade the autophagosome contents
• Amino acids, lipids, nucleotides, and sugars are exported back to the cytoplasm for reuse
• This recycling is critical during nutrient deprivation, providing substrates for essential biosynthesis

Key Components

Role in Peptide Research

MOTS-c

MOTS-c is a mitochondrial-derived peptide (encoded in the mitochondrial genome) that activates AMPK, which in turn inhibits mTORC1 and activates ULK1, promoting autophagy. MOTS-c's metabolic benefits — improved insulin sensitivity, exercise mimetic effects, stress resistance — are partly attributed to enhanced autophagic flux and mitochondrial quality control.

Epithalon

While epithalon's primary studied mechanism involves telomere biology and telomerase activation, autophagy and cellular senescence are interconnected. Senescent cells exhibit altered autophagy, and the relationship between telomere maintenance and autophagic capacity is an active area of investigation in longevity research.

SS-31 (Elamipretide)

SS-31 targets mitochondria and has been shown to improve mitochondrial function and reduce oxidative stress. By preserving mitochondrial membrane potential, SS-31 may reduce the burden of damaged mitochondria that require mitophagic clearance, indirectly influencing autophagy demand.

BPC-157

BPC-157 has been studied in the context of ischemia-reperfusion injury, where autophagy plays a dual role (protective at moderate levels, destructive at excessive levels). BPC-157's cytoprotective effects in these models may involve modulation of autophagy, though direct mechanistic evidence specific to autophagy regulation remains limited.

Fasting-Mimetic Context

Many peptide research protocols are discussed alongside intermittent fasting, which is one of the most potent physiological activators of autophagy. The interaction between fasting-induced autophagy and peptide administration timing is a topic of active discussion in the research community, particularly regarding whether GH secretagogues (which activate mTOR through IGF-1) might counteract fasting-induced autophagy.

Clinical Significance

• Neurodegeneration — Impaired autophagy contributes to the accumulation of toxic protein aggregates in Alzheimer's disease (amyloid-beta, tau), Parkinson's disease (alpha-synuclein), and Huntington's disease (huntingtin). Autophagy enhancement is a therapeutic strategy under investigation.
• Cancer — Autophagy plays a complex dual role: tumor-suppressive in early carcinogenesis (by maintaining genomic stability and clearing damaged organelles) but tumor-promoting in established cancers (by providing metabolic substrates under nutrient stress). Autophagy inhibitors (chloroquine, hydroxychloroquine) are being tested as cancer therapy adjuncts.
• Infectious disease — Xenophagy targets intracellular bacteria (Mycobacterium tuberculosis, Salmonella) and viruses. Some pathogens have evolved mechanisms to evade or exploit autophagy.
• Aging — Autophagy declines with age across organisms. Genetic enhancement of autophagy extends lifespan in model organisms. Caloric restriction, the most reproducible lifespan-extending intervention, activates autophagy as a central mechanism. See longevity protocol.
• Metabolic disease — Impaired hepatic autophagy contributes to non-alcoholic fatty liver disease. Impaired pancreatic beta-cell autophagy contributes to type 2 diabetes.
• Cardiac disease — Basal autophagy is essential for cardiomyocyte homeostasis. Both insufficient and excessive autophagy contribute to heart failure in different contexts.

Related Topics

• mTOR Pathway — The primary negative regulator of autophagy; mTOR inhibition activates autophagy
• Mitochondrial Function — Mitophagy is essential for mitochondrial quality control
• Telomere Biology — Autophagy and telomere maintenance are both longevity hallmarks
• PI3K/Akt Pathway — PI3K/Akt/mTOR axis suppresses autophagy under growth conditions